Colfax

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Posted $0.17 EPS from continuing operations and $0.54 of adjusted EPS

Colfax Corporation Announces Third Quarter 2021 Results

Starboard supports Colfax's plan to split into two businesses, but there are other ways to improve profitability.

Starboard Value spots fresh opportunities for diversified tech company Colfax

Colfax (CFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Colfax (CFX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

WILMINGTON, DE, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the third quarter of 2021 on the morning of Thursday, November 4, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-888-771-4371 (U.S. callers) and +1-847-585-4405 (International callers) and referencing the conference ID number 50243903 and through webcast via Colfax's website www.colfaxcorp.com under the “Investors” section.

Colfax Schedules Third Quarter 2021 Earnings Release and Conference Call

DALLAS--(BUSINESS WIRE)-- #djo--DJO® Expands Active, Adaptive Healing Offerings with Introduction of MedShape® DynaNail Hybrid™

DJO® Expands Active, Adaptive Healing Offerings with Introduction of MedShape® DynaNail Hybrid™

Colfax (CFX) to gain from robust demand, product innovation, cost actions and synergies from buyouts. Inflation in raw material costs and supply-chain issues are likely to hurt.

Colfax (CFX) to Gain From Demand & Buyouts Amid Cost Woes

AUSTIN, Texas--(BUSINESS WIRE)-- #djo--DJO, a leading global provider of medical technologies to get and keep people moving, today introduced its newest offering, EMPOWR Dual Mobility™.

DJO® Introduces New EMPOWR Dual Mobility™ Hip System at AAOS

Colfax (CFX) reported earnings 30 days ago. What's next for the stock?

Colfax (CFX) Up 2.9% Since Last Earnings Report: Can It Continue?

Builders FirstSource

Ciena

II-VI Incorporated

Jazz Pharmaceuticals

Lumentum Holdings

Neurocrine Biosciences

Papa John's

Signature Bank

Targa Resources

XPO Logistics

Want more stability and greater growth prospects in your investments? These top-rated mid-cap stocks offer the best of both worlds.

11 Mighty Mid-Cap Stocks for the Rest of 2021

Nordson

CFX vs. NDSN: Which Stock Is the Better Value Option?

CFX vs. NDSN: Which Stock Should Value Investors Buy Now?

Colfax's (CFX) Q2 earnings increase y/y on the back of strengthening end markets and margin improvement. For 2021, the company raises earnings and free cash flow projections.

Colfax (CFX) Tops Q2 Earnings & Sales Estimates, Hikes View

Colfax Corp (CFX) CEO Matthew Trerotola on Q2 2021 Results - Earnings Call Transcript

WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today the pricing of an underwritten secondary offering by certain of its stockholders (the “Selling Stockholders”) of 6,544,522 shares of the Company's common stock at a public offering price of $43.90 per share. The shares are expected to be delivered on or about August 2, 2021, subject to customary closing conditions.

Colfax Announces Pricing of Secondary Offering of 6,544,522 Shares of Common Stock

Colfax (CFX) delivered earnings and revenue surprises of 5.66% and 7.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Surpasses Q2 Earnings and Revenue Estimates

WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that certain of its stockholders (the “Selling Stockholders”) have commenced an underwritten secondary offering of 6,544,522 shares of the Company's common stock.

Colfax Announces Secondary Offering of 6,544,522 Shares of Common Stock

WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it has completed its previously announced acquisition of Mathys AG Bettlach (“Mathys”).

Colfax Completes Acquisition of Mathys AG Bettlach

WILMINGTON, DE, July 28, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the second quarter of 2021.

Colfax Corporation Announces Q2 Results, Increased Full Year Outlook, and Strategic Acquisition

Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Colfax (CFX) Beat Estimates Again in Its Next Earnings Report?

On Thursday, July 29, Colfax (NYSE:CFX) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.

A Preview Of Colfax's Earnings

Annapolis Junction, MD, July 14, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the second quarter of 2021 on the morning of Thursday, July 29, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 7659856 and through webcast via Colfax's website www.colfaxcorp.com under the “Investors” section.

Colfax Schedules Second Quarter 2021 Earnings Release and Conference Call

Flowserve

CFX vs. FLS: Which Stock Is the Better Value Option?

CFX or FLS: Which Is the Better Value Stock Right Now?

Colfax (CFX) is poised to benefit from strong demand for its products, solid product portfolio, acquired assets and healthy cash flows.

Colfax (CFX) Stock Up 19.3% YTD: What's Driving the Rally?

EVERTEC

Expeditors International of Washington

First Eagle Alternative Capital BDC Inc

Texas Instruments

The Dow Jones rose 30 points, while the S&P 500 rose 0.1%, and Nasdaq was flat. Make the most of this market with today's Top Buys from Q.ai's artificial intelligence.

Artificial Intelligence Ranks Colfax Corp And Evertec Inc Among Today's Top Buys

Colfax's (CFX) CEO Matt Trerotola on Q1 2021 Results - Earnings Call Transcript

Colfax's (CFX) Q1 earnings surpass estimates and improve year over year on sales and margin improvement. For 2021, it raises bottom-line projections.

News for Colfax Stock (CFX)